(Q24242173)

https://api.crossref.org/works/10.1002%2F14651858.CD004106.PUB3

Effect of ADRB2 polymorphisms on response to longacting beta2-agonist therapy: a pharmacogenetic analysis of two randomised studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004106.PUB3

Comparison of adjustable- and fixed-dose budesonide/formoterol pressurized metered-dose inhaler and fixed-dose fluticasone propionate/salmeterol dry powder inhaler in asthma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004106.PUB3

Effect of budesonide/formoterol maintenance and reliever therapy on asthma exacerbations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004106.PUB3

EXCEL: A randomised trial comparing salmeterol/fluticasone propionate and formoterol/budesonide combinations in adults with persistent asthma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004106.PUB3

Comparison of salmeterol/fluticasone propionate (FP) combination with FP+sustained release theophylline in moderate asthma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004106.PUB3

Budesonide/formoterol for maintenance and relief in uncontrolled asthma vs. high-dose salmeterol/fluticasone

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004106.PUB3

Formoterol 12 microg BID administered via single-dose dry powder inhaler in adults with asthma suboptimally controlled with salmeterol or on-demand salbutamol: a multicenter, randomized, open-label, parallel-group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004106.PUB3

The CONCEPT trial: a 1-year, multicenter, randomized,double-blind, double-dummy comparison of a stable dosing regimen of salmeterol/fluticasone propionate with an adjustable maintenance dosing regimen of formoterol/budesonide in adults with persiste

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004106.PUB3

Salmeterol/fluticasone stable-dose treatment compared with formoterol/budesonide adjustable maintenance dosing: impact on health-related quality of life

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004106.PUB3

Evaluation of different inhaled combination therapies (EDICT): a randomised, double-blind comparison of Seretide (50/250 microg bd Diskus vs. formoterol (12 microg bd) and budesonide (800 microg bd) given concurrently (both via Turbuhaler) in patien

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004106.PUB3

Early bronchodilatory effects of budesonide/formoterol pMDI compared with fluticasone/salmeterol DPI and albuterol pMDI: 2 randomized controlled trials in adults with persistent asthma previously treated with inhaled corticosteroids

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004106.PUB3

Comparison of combination inhalers vs inhaled corticosteroids alone in moderate persistent asthma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004106.PUB3

Onset of bronchodilation of budesonide/formoterol vs. salmeterol/fluticasone in single inhalers

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004106.PUB3

Canadian economic evaluation of budesonide-formoterol as maintenance and reliever treatment in patients with moderate to severe asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004106.PUB3

Budesonide/formoterol maintenance and reliever therapy: an effective asthma treatment option?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004106.PUB3

Fluticasone versus beclomethasone or budesonide for chronic asthma in adults and children

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004106.PUB3

Onset of action following formoterol Turbuhaler and salbutamol pMDI in reversible chronic airway obstruction

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004106.PUB3

Systematic review and meta-analysis of budesonide/formoterol in a single inhaler

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004106.PUB3

Long-acting beta2-agonists as an inhaled corticosteroid-sparing agent for chronic asthma in adults and children

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004106.PUB3

Measuring inconsistency in meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004106.PUB3

Long-acting beta2-agonists versus placebo in addition to inhaled corticosteroids in children and adults with chronic asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004106.PUB3

Inhaled dry-powder formoterol and salmeterol in asthmatic patients: onset of action, duration of effect and potency

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004106.PUB3

Inhaled corticosteroids: impact on asthma morbidity and mortality

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004106.PUB3

Long-acting beta2-agonists for chronic asthma in adults and children where background therapy contains varied or no inhaled corticosteroid

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004106.PUB3

Relationship between adherence to inhaled corticosteroids and poor outcomes among adults with asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004106.PUB3

7 January 2021

Salmeterol/fluticasone propionate combination therapy 50/250 microg twice daily is more effective than budesonide 800 microg twice daily in treating moderate to severe asthma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004106.PUB3

7 January 2021

Cost-effectiveness of salmeterol/fluticasone propionate combination product 50/250 microg twice daily and budesonide 800 microg twice daily in the treatment of adults and adolescents with asthma. International Study Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004106.PUB3

7 January 2021

Cost-effectiveness of budesonide/formoterol for maintenance and reliever asthma therapy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004106.PUB3

7 January 2021

Salmeterol versus formoterol in patients with moderately severe asthma: onset and duration of action

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004106.PUB3

7 January 2021

Cost effectiveness of budesonide/formoterol for maintenance and reliever therapy versus salmeterol/fluticasone plus salbutamol in the treatment of asthma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004106.PUB3

7 January 2021